lobbying_activities: 1991382

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1991382	f26ce0f8-49f7-42fb-8da2-e4e3ed9d466b	Q2	TARPLIN, DOWNS & YOUNG, LLC	304736	ABBVIE INC.	2017	second_quarter	HCR	PL114-255 - 21st Century Cures, implementation H.R. 1231/S. 456 - RACE for Children Act H.R 1628 - American Health Care Act of 2017 S. 771 - Improving Access to Affordable Prescription Drugs Act S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry From Keeping Drugs Expensive Act of 2017 S. 469 - Affordable and Safe Prescription Drug Importation act H.R. 749 - Lower Drug Costs Through Competition Act H.R. 2430 - FDA Reauthorization Act of 2017 Better Care Reconciliation Act of 2017 no specific bill - FDA implementation issues, 340B, biosimilars, prescription drug user fee reauthorization, non-interference, patient assistance	Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE	60000		0	0	2017-07-18T12:15:48.970000-04:00